1-Chlor-2-(1'-hydroxy-ethyl)-cyclohexen | 113684-03-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-Chlor-2-(1'-hydroxy-ethyl)-cyclohexen
• 英文别名: 1-(2-chloro-1-cyclohexenyl)ethanol；1-(2-chloro-1-cyclopentenyl)ethanol；1-(2-chloro-cyclohex-1-enyl)-ethanol；1-(2-chlorocyclohexen-1-yl)ethanol
• CAS: 113684-03-0
• 化学式: C₈H₁₃ClO
• 分子量: 160.644
• InChiKey: PMBVVTYFMYCHBT-UHFFFAOYSA-N

物化性质

• 沸点：
  248.4±23.0 °C(Predicted)
• 密度：
  1.10±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-Chlor-2-(1'-hydroxy-ethyl)-cyclohexen 生成 1-Chlor-2-(1'-chlor-ethyl)-cyclohexen
  参考文献：
  名称：

  摘要：

  DOI：
• 作为产物：
  描述：

  2-氯-1-甲酰基-1-环己烯 生成 1-Chlor-2-(1'-hydroxy-ethyl)-cyclohexen
  参考文献：
  名称：

  SCHULZE, KLAUS;RICHLER, CHRISLIAN;REIMERS, FRANK, Z. CHEM., 28,(1988) N 10, C. 363

  摘要：

  DOI：

文献信息

• Novel azole compound
  申请人：Yamamoto Takashi

  公开号：US20060194850A1

  公开（公告）日：2006-08-31

  Azole compounds represented by formula I: wherein ring A is isoxazole and the like, R1 is a substituted or unsubstituted aryl group and the like, R2 is a hydrogen atom and the like, and R3 is a substituted or unsubstituted alkyl group and the like, and pharmaceutically acceptable salts thereof inhibit the physiological activity of lysophosphatidic acid (LPA), and are useful as for the prophylaxis or treatment of diseases in which inhibition of the physiological activity of LPA is useful for the prophylaxis or treatment thereof, such as diseases involving the LPA receptor.

  由公式I表示的唑类化合物： 其中环A是异噁唑等，R1是取代的或未取代的芳基团等，R2是氢原子等，R3是取代的或未取代的烷基团等，以及药用可接受的盐，可以抑制溶血磷脂酸（LPA）的生理活性，并且用于预防或治疗抑制LPA生理活性对预防或治疗有用的疾病，如涉及LPA受体的疾病。
• [EN] LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DES RÉCEPTEURS D'ACIDE LYSOPHOSPHATIDIQUE
  申请人：INTERMUNE INC

  公开号：WO2013025733A1

  公开（公告）日：2013-02-21

  Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.

  提供了化合物、制备这种化合物的方法、包含这种化合物的药物组合物和药物，以及使用这种化合物治疗、预防或诊断与一种或多种赖氨酸磷脂酸受体相关的疾病、紊乱或状况的方法。
• Polycyclic antagonists of lysophosphatidic acid receptors
  申请人：Amira Pharmaceuticals, Inc.

  公开号：US08058300B2

  公开（公告）日：2011-11-15

  Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.

  本文介绍的是一些可以拮抗溶血磷脂酰肌酸受体的化合物。还介绍了包括上述化合物的药物组合物和药物，以及使用这些拮抗剂的方法，单独或与其他化合物联合治疗依赖或介导溶血磷脂酰肌酸的疾病或症状。
• POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS
  申请人：HUTCHINSON John Howard

  公开号：US20120015991A1

  公开（公告）日：2012-01-19

  Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.

  本文描述了一些抗溶血磷脂酸受体的化合物。还描述了包括上述化合物的药物组合物和药物，以及使用这些拮抗剂的方法，单独或与其他化合物组合，用于治疗LPA依赖性或LPA介导的疾病或病症。
• NOVEL AZOLE COMPOUND
  申请人：YAMAMOTO Takashi

  公开号：US20130041000A1

  公开（公告）日：2013-02-14

  Azole compounds represented by formula I: wherein ring A is isoxazole and the like, R1 is a substituted or unsubstituted aryl group and the like, R2 is a hydrogen atom and the like, and R3 is a substituted or unsubstituted alkyl group and the like, and pharmaceutically acceptable salts thereof inhibit the physiological activity of lysophosphatidic acid (LPA), and are useful as for the prophylaxis or treatment of diseases in which inhibition of the physiological activity of LPA is useful for the prophylaxis or treatment thereof, such as diseases involving the LPA receptor.

  公式I所代表的氮唑化合物，其中环A是异噁唑等，R1是取代或未取代的芳基基团等，R2是氢原子等，R3是取代或未取代的烷基基团等，以及其药学上可接受的盐，能够抑制溶血磷脂酸（LPA）的生理活性，可用于预防或治疗需要抑制LPA生理活性的疾病，例如涉及LPA受体的疾病。